Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1735663 | 1.00 | LMNA (0.48) | LMNASMN1; SMN2HTTMAPTKDM4E | |
| SCHEMBL1734702 | 0.87 | ALDH1A1 (0.51) | LMNASMN1; SMN2HTTMAPTKDM4E | |
| SCHEMBL1734700 | 0.87 | ALDH1A1 (0.51) | LMNASMN1; SMN2HTTMAPTKDM4E | |
| SCHEMBL1736737 | 0.86 | CHRM4 (0.49) | LMNASMN1; SMN2HTTMAPTKDM4E | |
| SCHEMBL1736735 | 0.86 | CHRM4 (0.49) | LMNASMN1; SMN2HTTMAPTKDM4E | |
| SCHEMBL1735689 | 0.86 | CHRM4 (0.44) | LMNASMN1; SMN2MAPTL3MBTL1MEN1 | |
| SCHEMBL1735083 | 0.84 | HSD11B1 (0.53) | CA12CA1CA2CA9 | |
| SCHEMBL1735079 | 0.84 | HSD11B1 (0.53) | CA12CA1CA2CA9 | |
| SCHEMBL1734689 | 0.82 | CPT2 (0.51) | LMNASMN1; SMN2HTTMAPTKDM4E | |
| SCHEMBL1734688 | 0.82 | CPT2 (0.51) | LMNASMN1; SMN2HTTMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142533-B1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | claimed |
| WO-2011069003-A3 | METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-27 | — | — | WO | claimed |
| US-7625902-B2 | Imidazolidinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | claimed |
| US-20080242677-A1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-02 | — | — | US | claimed |
| EP-2142533-B1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011069003-A3 | METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-27 | — | — | WO | disclosed |
| US-7625902-B2 | Imidazolidinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080242677-A1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242677-A1 | IMIDAZOLIDINONE DERIVATIVES | NR1H2, NR1H3, NR1I2 | LMNA 1252/4885SMN1; SMN2 3502/4885HTT 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.